Interleukin-13 (human, recombinant)

Interleukin-13 (IL-13) is a cytokine that is involved in type 2 immunity. It is a secreted protein that is mainly expressed by activated T cells, but is also produced by mast cells, basophils, eosinophils, and nuocytes. Two amino acid sequences of IL-13 have been reported, one is 132 amino acids in length and the other with 14 additional amino acids at the N-terminus resulting in a 146 amino acid protein. IL-13 binds to a heterodimer of IL-4 receptor alpha (IL-4Ralpha) and IL-13Ralpha1 to initiate intracellular signaling through the JAK/STAT or PI3K pathways. It also binds to the decoy receptor, IL-13Ralpha2, to initiate TGF-beta signaling. IL-13 has roles in host defense against helminth parasites, airway hyperresponsiveness, antitumor immunity, tissue remodeling, and mucus production. It induces the proliferation of activated B lymphocytes and the production of IgG and IgM by B cells co-cultured with T cells. Knockout of Il13 increases survival and decreases hepatic fibrosis in a mouse model of S. mansoni infection. SNPs in IL13 are associated with asthma. Protein levels of IL-13 are increased in primary and metastatic tumors compared with normal ovarian tissue in patients with ovarian cancer. Cayman's Interleukin-13 (human, recombinant) protein is based on the 132 amino acid sequence and can be used for cell-based assay applications.Synonyms: ALRH Protein, IL-13. Purity: >92% estimated by SDS-PAGE. Endotoxin Testing: <1.0 EU/µg determined by the LAL endotoxin assay. Source: Active recombinant human IL-13 expressed in CHO cells. Amino Acids: 1-132. MW: 12.5 kDa. Formulation: (Request formulation change), Lyophilized from sterile PBS, pH 7.4. UniProt Accession #: P35225.